Etomidate (USAN, INN, BAN) (marketed as Amidate) is a short-acting intravenous anaesthetic agent used for the induction of general anaesthesia and sedation for short procedures such as reduction of dislocated joints, tracheal intubation, and cardioversion.
CAT No: 10-101-136
CAS No:33125-97-2 (net)
Synonyms/Alias:1-[(1R)-1-Phenylethyl]-1Himidazole-5-carboxylic acid ethyl ester; (+)-Ethyl 1-(α-methyl-benzyl)-imidazole-5-carboxylate
Etomidate is a potent imidazole-derived compound recognized for its rapid-acting anesthetic properties and unique pharmacological profile. Characterized by its ability to induce hypnosis with minimal cardiovascular and respiratory depression, Etomidate has become an indispensable tool in both research and experimental settings. Its chemical structure allows for high lipid solubility, facilitating swift penetration of the blood-brain barrier and resulting in a prompt onset of action. Owing to its favorable safety margin and predictable pharmacodynamics, this compound is frequently chosen for applications where precise control over sedation depth is required. Etomidate's mechanism of action primarily involves modulation of gamma-aminobutyric acid (GABA) receptors, leading to enhanced inhibitory neurotransmission in the central nervous system, which underscores its value for a broad spectrum of scientific investigations.
Neuroscience research: Etomidate serves as a critical agent in neuroscience studies focused on elucidating the mechanisms of anesthesia and consciousness. By acting as a positive allosteric modulator of GABA_A receptors, it provides researchers with a reliable means to induce reversible loss of consciousness in animal models. This enables the investigation of neural circuitry, synaptic plasticity, and brain connectivity under controlled anesthetic conditions. The compound's rapid onset and short duration of action are particularly advantageous for experiments requiring repeated or time-sensitive interventions, allowing for detailed mapping of neural responses to anesthetic exposure and recovery.
Pharmacological profiling: In pharmacological studies, Etomidate is employed to characterize the effects of anesthetics on various receptor subtypes and signaling pathways. Its selective action on GABAergic transmission, with minimal impact on other neurotransmitter systems, makes it an ideal reference compound for dissecting the contributions of inhibitory neurotransmission to overall anesthetic efficacy. Researchers utilize it to compare the pharmacodynamics of novel anesthetic agents, assess drug-drug interactions, and investigate potential mechanisms of anesthetic-induced neuroprotection or neurotoxicity. The clarity provided by Etomidate's targeted mode of action facilitates the development of new hypotheses regarding central nervous system modulation.
Endocrine function studies: The ability of Etomidate to transiently suppress adrenal steroidogenesis via inhibition of 11β-hydroxylase is leveraged in research exploring the hypothalamic-pituitary-adrenal (HPA) axis. By administering it in experimental protocols, scientists can examine the acute effects of corticosteroid depletion on stress responses, immune function, and metabolic regulation. This targeted suppression provides a valuable model for studying adrenal insufficiency and for evaluating the compensatory mechanisms activated during periods of impaired glucocorticoid synthesis. The compound's reversible action ensures that such investigations can be conducted with precise temporal control.
Cardiovascular research: Etomidate is widely used in cardiovascular studies due to its minimal impact on heart rate and blood pressure compared to other anesthetic agents. This property allows researchers to isolate the direct effects of experimental interventions on cardiac function without confounding influences from anesthetic-induced hemodynamic changes. Studies involving myocardial ischemia, arrhythmias, or cardiac output frequently utilize it as the anesthetic of choice, ensuring the integrity of cardiovascular measurements and facilitating reproducible results across different experimental models.
Toxicology and safety assessment: In toxicological research, Etomidate acts as a reference compound for evaluating the safety profiles of new anesthetic candidates. Its well-characterized pharmacokinetics and low propensity for adverse effects provide a benchmark against which the toxicity and side effect profiles of investigational agents can be measured. Employing it in dose-response and safety screening protocols helps to identify compounds with improved therapeutic indices and reduced risk of complications, thereby guiding the selection of promising candidates for further development.
Behavioral studies: Etomidate's rapid and reversible hypnotic effects are harnessed in behavioral neuroscience to investigate the impact of anesthesia on cognitive, sensory, and motor functions. Researchers use it to induce temporary states of unconsciousness or sedation in animal models, enabling the assessment of post-anesthetic recovery, memory retention, and learning processes. Its predictable pharmacological behavior supports reproducible experimental designs, while its minimal residual effects facilitate longitudinal studies on behavioral adaptation and neuroplasticity following repeated anesthetic exposure. Through these diverse applications, Etomidate continues to play a pivotal role in advancing scientific understanding across multiple domains.
This review focuses on the unique clinical and molecular pharmacology of etomidate. Among general anesthesia induction drugs, etomidate is the only imidazole, and it has the most favorable therapeutic index for single bolus administration. It also produces a unique toxicity among anesthetic drugs-- inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating anesthetic effects of etomidate in the central nervous system are specific γ-aminobutyric acid type A receptor subtypes. Amino acids forming etomidate binding sites have been identified in transmembrane domains of these proteins. Etomidate binding site structure models for the main enzyme mediating etomidate adrenotoxicity have also been developed. Based on this deepening understanding of molecular targets and actions, new etomidate derivatives are being investigated as potentially improved sedative-hypnotics or for use as highly selective inhibitors of adrenal steroid synthesis.
Forman, S. A. (2011). Clinical and molecular pharmacology of etomidate. Anesthesiology: The Journal of the American Society of Anesthesiologists, 114(3), 695-707.
Etomidate is an intravenous anesthetic agent released for clinical use in the United States in 1972. Its popularity in clinical practice is the result of its beneficial effects on intracerebral dynamics with limited effects on hemodynamic function. These properties have made it a safe and effective anesthetic induction agent in both adult and pediatric patients with altered myocardial performance, congenial heart disease, or hypovolemia. However, recent concern has been expressed regarding its effects on the endogenous production of corticosteroids and the impact of that effect on patient outcomes. The following manuscript reviews clinical reports regarding etomidate use in the pediatric population and discusses recent concerns regarding its effects on corticosteroid metabolism and the implications of such effects for clinical use.
Tobias, J. D. (2015). Etomidate in pediatric anesthesiology: Where are we now?. Saudi journal of anaesthesia, 9(4), 451.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More